PAVmed Inc. (NASDAQ:PAVM) Short Interest Up 299.7% in June

PAVmed Inc. (NASDAQ:PAVM) saw a significant growth in short interest during the month of June. As of June 30th, there was short interest totaling 33,650 shares, a growth of 299.7% from the June 15th total of 8,418 shares. Currently, 3.9% of the company’s shares are short sold. Based on an average daily trading volume, of 35,155 shares, the short-interest ratio is presently 1.0 days.

Institutional Investors Weigh In On PAVmed

A hedge fund recently raised its position in PAVmed stock. Jane Street Group LLC grew its stake in PAVmed Inc. (NASDAQ:PAVM) by 392.9% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 52,676 shares of the company’s stock after acquiring an additional 41,990 shares during the period. Jane Street Group LLC owned about 0.31% of PAVmed worth $32,000 as of its most recent filing with the SEC. 19.93% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have issued reports on PAVM. Wall Street Zen raised PAVmed from a “sell” rating to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings reissued a “sell (d)” rating on shares of PAVmed in a research report on Tuesday, April 21st. Finally, Ascendiant Capital Markets dropped their price objective on shares of PAVmed from $65.00 to $56.00 and set a “buy” rating for the company in a report on Monday, June 8th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, PAVmed currently has a consensus rating of “Hold” and a consensus target price of $56.00.

PAVmed Trading Down 1.8%

Shares of PAVM stock traded down $0.10 during trading on Monday, hitting $5.50. 6,195 shares of the stock traded hands, compared to its average volume of 23,012. PAVmed has a 52-week low of $3.85 and a 52-week high of $28.44. The firm has a market capitalization of $5.50 million, a P/E ratio of -0.15 and a beta of 0.54. The firm’s fifty day moving average price is $5.78 and its 200-day moving average price is $8.07. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.02 and a quick ratio of 2.02.

PAVmed (NASDAQ:PAVM) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.17) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.48). The business had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.07 million. PAVmed had a negative return on equity of 146.19% and a negative net margin of 21,914.12%. As a group, research analysts forecast that PAVmed will post -2.74 earnings per share for the current fiscal year.

About PAVmed

PAVmed Inc is a clinical-stage medical technology company focused on acquiring, developing and commercializing innovative medical devices aimed primarily at gastrointestinal endoscopy and related therapeutic areas. Its portfolio includes FDA-cleared products such as EsoFLIP® Distensibility System for the treatment of esophageal strictures and MUSE™ (Medigus Ultrasonic Surgical Endostapler) for endoscopic fundoplication in gastroesophageal reflux disease (GERD). In addition to its gastrointestinal franchise, PAVmed is advancing early-stage programs targeting indications in oncology, urology and dermatology.

Founded in 2012, PAVmed has built its pipeline through internal research and development as well as strategic collaborations and acquisitions.